Scibase: Strong start to the year - Redeye

Redeye changes our short-term estimates slightly because of a better outcome than expected in the first quarter. The sales development was strong and a healthy gross margin was reported. The costs were in line apart from higher R&D costs. We reiterate our Base case at SEK 12 per share and unchanged fair value range of SEK 5 – 20 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/841875/scibase-strong-start-to-the-year?utm_source=finwire&utm_medium=RSS